AbbVie faces growth challenges with mixed Q2 results. Click here for a full investment analysis of ABBV stock.

AbbVie has announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company ...

AbbVie (ABBV) announced submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for accelerated ...

Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...

AbbVie ABBV has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual ...

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...

Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating on September 13. David ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...

AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate ...